Are physicians "easy marks"? Quantifying the effects of detailing and sampling on new prescriptions

Management Science

Volumn 50, Issue 12, 2004, Pages 1704-1715

  Mizik, Natalie ^a   Jacobson, Robert ^b  

^a Howard Hughes Medical Institute   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Pharmaceutical marketing; Salesforce effectiveness

Indexed keywords

PHARMACEUTICAL MARKETING; SALES REPRESENTATIVES; SALESFORCE EFFECTIVENESS; SCIENTIFIC EVIDENCES;

COMPETITION; DRUG PRODUCTS; LAWS AND LEGISLATION; SALES; SAMPLING; STATISTICAL METHODS;

MARKETING;

EID: 11844304992     PISSN: 00251909     EISSN: None     Source Type: Journal    
DOI: 10.1287/mnsc.1040.0281     Document Type: Article

References (31)

1. Anderson, T. W., Cheng Hsiao. 1982. Formulation and estimation of dynamic models using panel data. J. Econometrics 18(1) 47-82.
2. Arellano, Manuel. 2003. Panel Data Econometrics. Oxford University Press, Inc., New York.
3. Arellano, Manuel, Stephen Bond. 1991. Some tests of specification for panel data: Monte Carlo evidence and an application to employment equations. Rev. Econom. Stud. 58(194) 277-297.
4. Avorn, Jerry, Milton Chen, Robert Hartley. 1982. Commercial versus scientific sources of influence on the prescribing behavior of physicians. Amer. J. Medicine 73(July) 4-8.
5. Azoulay, Pierre. 2002. Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4) 551-594.
6. Berndt, Ernst R., Robert S. Pindyck, Pierre Azoulay. 2003. Consumption externalities and diffusion in pharmaceutical markets: Antiulcer drugs. J. Indust. Econom. 51(2) 243-270.
7. Campbell, Margaret C., Amna Kirmani. 2000. Consumers' use of persuasion knowledge: The effects of accessibility and cognitive capacity on perceptions of an influence agent. J. Consumer Res. 27(June) 69-83.
8. Chren, Mery-Margaret, C. Seth Landefeld. 1994. Physicians' behavior and their interactions with drug companies: A controlled study of physicians who requested additions to a hospital drug formulary. J. Amer. Medical Assoc. 271(9) 684-689.
9. Connelly, Donald P., Eugene C. Rich, S. P. Curley, J. T. Kelley. 1990. Knowledge resource preferences of family physicians. J. Family Practice 30(3) 353-359.
10. Dholakia, Ruby Roy, Brian Sternthal. 1977. Highly credible sources: Persuasive facilitators or persuasive liabilities? J. Consumer Res. 3(March) 223-232.
11. Eagley, Alice H., Shelly Chaiken, 1975. An attribution analysis of the effect of communicator characteristics on the opinion change: The case of communicator attractiveness. J. Personality Soc. Psych. 32(July) 136-144.
12. Elling, Martin E., Holly J. Fogle, Charles S. McKhann, Chris Simon. 2002. Making more of pharma's sales force. McKinsey Quart. 3 86-95.
13. Friestad, Marian, Peter Wright. 1994. The persuasion knowledge model: How people cope with persuasion attempts, J. Consumer Res. 21(June) 1-31.
14. Gold, Russell. 2001. States battling high drug costs appeal to doctors. Wall Street Journal (August 22) B1, B8.
15. Gonul, Fusun F., Franklin Carter, Elina Petrova, Kanan Srinivasan. 2001. Promotion of prescription drugs and its impact of physician choice behavior. J. Marketing 65(3) 79-90.
16. Hausman, Jerry A. 1978. Specification tests in econometrics. Econometrica 46 1251-1272.
17. Hensley, S. 2002. Sorry, Doc, no dinners-to-go - Drug sales reps begin building a new marketing playbook. Wall Street Journal (April 23) D4.
18. IMS Health. 2003. IMS review: Steady but not stellar. Medical Marketing Media 38(May) 50-63.
19. Krinsky, Itzhak, A. Leslie Robb. 1986. On approximating the statistical properties of elasticities. Rev. Econom. Statist. 68(3) 715-719.
20. Lichstein, Peter R., Robert C. Turner, Kevin O'Brien. 1992. Impact of pharmaceutical company representatives on internal medicine residency programs: A survey of residency program directors. Arch. Internal Medicine 152(5) 1009-1013.
21. McKinley, W. Paul, David L. Schiedermayer, Nicole Lurie, Deborah E. Simpson, Jesse L. Goldman, Eugene C. Rich. 1990. Attitudes of internal medicine faculty and residents toward professional interactions with pharmaceutical sales representatives. J. Amer. Medical Assoc. 264(13) 1693-1697.
22. Narayanan, Sridhar, Ramarao Desiraju, Pradeep K. Chintagunta. 2003. ROI implications for pharmaceutical promotional expenditures: The case of second-generations antihistamines. Working paper, University of Chicago, Chicago, IL.
23. Parsons, Leonard Jon, Piet Vanden Abeele. 1981. Analysis of sales call effectiveness. J. Marketing Res. 18(February) 107-113.
24. Pear, Robert. 2003. Congress weighs drug comparisons. New York Times (August 24) 1, 18.
25. Peay, Marilyn Y., Edmund R. Peay. 1990. Patterns of preference for information sources in the adoption of a new drugs by specialists. Social Sci. Medicine 31(4) 467-476.
26. Powers, Roxann. 1998. Time with drug representatives affects prescribing. 21st Annual Meeting of the Society of General Internal Medicine, Chicago, IL.
27. Rizzo, John A. 1999. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. J. Law Econom. 42(April) 89-116.
28. Washington Post. 2002. U.S. issues warning to drug industry. (October 2) El.
29. Wickens, Michael R. 1972. A note on the use of proxy variables. Econometrica 40(4) 759-761.
30. Wotruba, Thomas R. 1982. Comment on "Analysis of sales force effectiveness." J. Marketing Res. 19(November) 595-596.
31. Zigler, Michael G., Pauline Lew, Brian C. Singer. 1995. The accuracy of drug information from pharmaceutical sales representatives. J. Amer. Medical Assoc. 273(16) 1296-1298.